FDA Accepts Supplement Application for ENSPRYNG (Satralizumab)
The FDA has accepted the supplemental application for ENSPRYNG (satralizumab) submitted by Genentech.
Therapeutic Area
Therapeutic area intelligence for Autoimmune Disorders with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.